HFCWO is most commonly used in children with chronic pulmonary conditions. Key beneficiaries include those diagnosed with:
Cystic fibrosis Primary ciliary dyskinesia Chronic obstructive pulmonary disease (COPD) with significant mucus production Neuromuscular diseases like muscular dystrophy
Children who have difficulty with airway clearance due to these conditions may experience improved lung function and reduced infection rates with the use of HFCWO.
